Many patients can still experience UA-RINV despite prophylactic therapy; therefore, researchers explored the effectiveness and safety of dual prophylactic therapy with an NK1 receptor antagonist and a 5-HT3 receptor antagonist.
The Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) have updated their recommendations for the prevention of nausea and vomiting following multiple-day chemotherapy.
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
[Cancer Management and Research] This review focuses on dronabinol and its role in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Loss of appetite and not eating are difficult aspects of cancer for patients' loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|